Revance Therapeutics (RVNC) Tops Q3 EPS by 5c

Revance Therapeutics (NASDAQ: RVNC) reported Q3 EPS of ($1.10), $0.05 better than the analyst estimate of ($1.15). Revenue for the quarter came in at $19.7 million versus the consensus estimate of $20.29 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI